Men showed a stronger association than women. The population attributable fraction

for colorectal cancer of BMI ≥ 25.0 was 3.6% (95% CI 1.91–5.30) for men and 2.6% (95% CI 0.74–4.47) for women.[14] In Japan, during the past 20–30 years, selleck compound the frequency of patients presenting with NAFLD has increased gradually in proportion to the increase in the population with obesity.[15] The prevalence of NAFLD in men is 30% and that in women is 15%. There is also a gender difference in the age distribution; in men, the incidence of fatty liver remains unchanged from their 30s to 60s, whereas in women, the prevalence of fatty liver increases gradually with age and in their 60s and beyond reaches nearly the same level as in men. The prevalence of NAFLD is noted in only 2.7% of non-obese subjects with a BMI < 23 and is 10.5% in those with a BMI of 23–25, 34.6% in those with a BMI of 25–30, and 77.6% in highly obese subjects with a BMI ≥ 30.[16]

The severity of fat deposition in the liver is positively correlated with visceral fat accumulation in both obese and non-obese subjects.[17] The prevalence of NAFLD is 60–80% in subjects with visceral fat accumulation evaluated by waist circumstance (men, over 85 cm; women, over 90 cm) or VFA (over 100 cm2 at the umbilicus). From the recent studies, the number of NAFLD patients in Japan is estimated to be 10 million, and around 2 million are considered to have non-alcoholic

steatohepatitis (NASH). The incidence of complications of lifestyle-related diseases (diabetes, HKI-272 order hypertension, or dyslipidemia) in NAFLD patients is 50–60%, and no significant difference is seen in individual factors.[16] We recently reported that in a community-based, longitudinal study of 6403 Japanese subjects, the cumulative onset rate of NAFLD was significantly higher in the high BMI group than in the low BMI group in both sexes (in men, odds ratio is 1.22, 95% CI 1.13–1.31, and in women, odds ratio is 1.33, 95% CI 1.26–1.40).[18] find more Recent studies have suggested that obesity may play a role in the development of liver cancer in chronic liver disease patients and in the general population. Among 14 cohort and case-control studies identified in Japan, the summary RR of hepatocellular carcinoma (HCC) for 1 kg/m2 BMI increase was estimated at 1.13 (95% CI 1.07–1.20), and overweight/obese individuals had an RR of 1.74 (95% CI 1.33–2.28) compared with those who had normal/low weight.[19] NASH can progress to HCC. In a cross-sectional multicenter study in Japan, 87 patients (62% men and 38% women) were diagnosed with NASH and developed HCC; obesity, diabetes, and hypertension were present in 62%, 59%, and 55% patients, respectively.[20] Dietary and behavioral modification is effective for body weight loss and for the improvement of obesity-related GI liver diseases.

Men showed a stronger association than women. The population attributable fraction

for colorectal cancer of BMI ≥ 25.0 was 3.6% (95% CI 1.91–5.30) for men and 2.6% (95% CI 0.74–4.47) for women.[14] In Japan, during the past 20–30 years, click here the frequency of patients presenting with NAFLD has increased gradually in proportion to the increase in the population with obesity.[15] The prevalence of NAFLD in men is 30% and that in women is 15%. There is also a gender difference in the age distribution; in men, the incidence of fatty liver remains unchanged from their 30s to 60s, whereas in women, the prevalence of fatty liver increases gradually with age and in their 60s and beyond reaches nearly the same level as in men. The prevalence of NAFLD is noted in only 2.7% of non-obese subjects with a BMI < 23 and is 10.5% in those with a BMI of 23–25, 34.6% in those with a BMI of 25–30, and 77.6% in highly obese subjects with a BMI ≥ 30.[16]

The severity of fat deposition in the liver is positively correlated with visceral fat accumulation in both obese and non-obese subjects.[17] The prevalence of NAFLD is 60–80% in subjects with visceral fat accumulation evaluated by waist circumstance (men, over 85 cm; women, over 90 cm) or VFA (over 100 cm2 at the umbilicus). From the recent studies, the number of NAFLD patients in Japan is estimated to be 10 million, and around 2 million are considered to have non-alcoholic

steatohepatitis (NASH). The incidence of complications of lifestyle-related diseases (diabetes, selleck hypertension, or dyslipidemia) in NAFLD patients is 50–60%, and no significant difference is seen in individual factors.[16] We recently reported that in a community-based, longitudinal study of 6403 Japanese subjects, the cumulative onset rate of NAFLD was significantly higher in the high BMI group than in the low BMI group in both sexes (in men, odds ratio is 1.22, 95% CI 1.13–1.31, and in women, odds ratio is 1.33, 95% CI 1.26–1.40).[18] selleck inhibitor Recent studies have suggested that obesity may play a role in the development of liver cancer in chronic liver disease patients and in the general population. Among 14 cohort and case-control studies identified in Japan, the summary RR of hepatocellular carcinoma (HCC) for 1 kg/m2 BMI increase was estimated at 1.13 (95% CI 1.07–1.20), and overweight/obese individuals had an RR of 1.74 (95% CI 1.33–2.28) compared with those who had normal/low weight.[19] NASH can progress to HCC. In a cross-sectional multicenter study in Japan, 87 patients (62% men and 38% women) were diagnosed with NASH and developed HCC; obesity, diabetes, and hypertension were present in 62%, 59%, and 55% patients, respectively.[20] Dietary and behavioral modification is effective for body weight loss and for the improvement of obesity-related GI liver diseases.

, MD (Abstract Reviewer) Speaking and Teaching: Salix, Merck, Vertex; Advisory Committee or Review Panel: Kadmon Gordon, Stuart C., MD (Clinical Research Committee, Abstract Reviewer) Advisory Committee or Review Panel: Gilead, Merck;

Consulting: Achillion, CVS Caremark, Speaking and Teaching: Merck, Gilead, Vertex Gorham, James D., MD see more (Abstract Reviewer) Nothing to disclose Green, Richard M., MD (Federal Agencies Liaison Committee) Nothing to disclose Greenbaum, Linda, MD (Abstract Reviewer) Employment: Janssen (spouse) Guevara, Monica, MD (Program Evaluation Committee) Nothing to disclose Hagedorn, Curt H., MD (Abstract Reviewer) Nothing to disclose Hamilton, James P., MD (Program Evaluation Committee) Lectures: Advanced Studies in Medicine Hepatitis B CME Royalties: UpToDate Hardikar, Winita, MD, PhD (Surgery and Liver Transplantation Committee) Nothing to disclose Haynes-Williams, Vanessa E., MSN (Hepatology Associates Committee) Nothing to Selleckchem SB203580 disclose Heimbach, Julie, MD (Abstract Reviewer) Nothing to disclose Heller, Theo, MD (Abstract Reviewer) Nothing to disclose Heuman, Douglas, MD (Abstract Reviewer) Consulting: Bayer AG; Speaking and Teaching: Otsuka America Pharmaceutical, Astellas;

Grants/Research Support: Novartis, SciClone, Scynexis, Bristol-Myers Squibb, MannKind, Wyeth, Ocera Therapeutics, Salix, Globelmmune, InterMune, Hoffman-LaRoche, UCB, Celgene, Centocor, Millennium Research Group, Osiris Pharmaceuticals, Otsuka America Pharmaceutical, Exelixis, Bayer AG Horne, Patrick M., MSN ARNP

(Annual Meeting Education Committee) Scientific Consultant: learn more Vertex Horslen, Simon P., MD (Surgery and Liver Transplantation Committee) Nothing to disclose Howell, Charles D., MD (Annual Meeting Education Committee) Advisory Board: Genetech; Grants/ Research Support: Boehringer Ingelheim Pharmaceuticals, Esal, Ikaria, Bristol-Myers Squibb; Leadership in Related Society: World Journal of Gastroenterology Hu, Ke-Qin, MD (Program Evaluation Committee) Speaking and Teaching: Bristol-Myers Squibb, Gilead, Genetech, Vertex, Bayer/Onyx Grants/Research Support: Bristol-Myers Squibb, Gilead, Genetech, Vertex, Bayer/Onyx, Merck Hubbard, Sarah B., PA-C (Abstract Reviewer) Advisory Committees or Review Panels: Vertex Pharmaceuticals Ioannou, George, MD (Clinical Research Committee) Nothing to disclose Iwakiri, Yasuko, MD (Abstract Reviewer) Nothing to disclose Janssen, Harry LA., MD (Abstract Reviewer) Consulting: DebioPharm, Abbot, Kirin, Medtronic, Santaris, Roche, Novartis, Bristol-Myers Squibb; Grants/Research Support: Gilead, Bristol-Myers Squibb; Consulting: Gilead, Novartis, Roche, Santaris, Medtronic, Anadys, Innogenetics Jensen, Donald M.

05). In the Elevator Counting test, all controls and patients without MHE got the

maximal score of 7. Four of the eleven patients with MHE who performed the test obtained lower scores (4, 5, 6, and 6, respectively), indicating impaired sustained attention. In the bimanual coordination test, control subjects completed the task in 1.7 ± 0.1 minutes. Patients without MHE needed 2.1 ± 0.1 minutes. Patients with MHE showed a reduction in bimanual coordination. They needed 2.4 ± 0.3 minutes, which was higher than for control Protein Tyrosine Kinase inhibitor subjects (P < 0.05, first study; P < 0.001, follow-up study) and for patients without MHE in follow-up study (P < 0.001)(Fig. 3A). In the visuomotor coordination test, controls completed the task in 2.2 ± 0.1 minutes. Score was not affected in patients without MHE, who needed 2.5 ± 0.1 minutes. Patients with MHE needed more time (3.4 ± 0.31 min; P < 0.05, first study; P SB525334 < 0.001, follow-up study) (Fig. 3B). Critical flicker frequency was not different in patients without MHE (41 ± 4 Hz; n = 36) than in controls (44 ± 4 Hz; n = 13). CFF was reduced (P < 0.001) in

patients with MHE to 37 ± 4 Hz (n = 20). Statistical correlations between the different parameters analyzed are shown in Table 3. To assess whether MMN changes in parallel with MHE and/or performance in attention tests, we performed a longitudinal follow-up study. The effects of MHE on MMN latency, amplitude, and area and on performance on the Stroop, Map see more Search, and bimanual and visuomotor coordination tests were the same as in the first study (Figs 1-4). In the follow-up study, 5 patients with MHE remained in MHE, 5 died, and 4 improved. Three of these patients (PR51, A41, and A28) improved the PHES because of improved performance in attention

tests and also showed increased MMN area (Fig. 4; Table 4). In 1 patient (PR27) who improved PHES because of better motor coordination without changes in attention tests, MMN area was not significantly altered (Table 4; Fig. 4). Four patients who did not show MHE in the first study (A40, PR41, A49, and A23) showed worse performance in attention tests in the second study, with reduced PHES that reached −8 (MHE) in 1 of them (A23). MMN area was reduced in these patients in parallel with deterioration of attention (Table 4; Fig. 4). These data show that MMN area changed (i.e., increases or decreases), from the first to the second study, in parallel with changes (i.e., improvement or worsening) in performance in attention tests in the same patients. Logistic regression analyses show that MMN area predicts performance in attention tests NCT-A (P = 0.002; 95% CI = 1.015-1.071), NCT-B (P < 0.0001; 95% CI = 1.010-1.035), and Stroop incongruent (P = 0.023; 95% CI = 1.003-1.030) and in the PHES (P < 0.001; 95% CI = 1.017-1.062). MMN area does not predict performance in visuomotor or bimanual coordination, in the Map Search, or in CFF.

6 cases of anastomotic stenosis distal PSV was significantly increased (PSV: 250 ± 102 cm/s), P < 0.01, Hepatic artery left tributary speed increased in some cases, mainly for the envelope is not Volasertib research buy smooth, the resistance index (RI) reduce (RI < 0.5), P < 0.01. Two false-positive cases mainly for lower RI < 0.5, The reason is moderate aortic stenosis after further examination; one missed cases without clear images of anastomotic, the left branch of the hepatic artery RI is normal, after further examination, we found the moderate aortic regurgitation caused sonographer

miscarriage of justice. Conclusion: Hepatic Hemodynamic checks help to find early hepatic artery complications after liver transplantation, but there are still some deficiencies, especially extrahepatic factors interfereing with the hemodynamic

parameters should caught clinicians attention. Key Word(s): 1. liver transplantation; 2. anastomotic stenosis; 3. hemodynamic; 4. resistance index; Presenting Author: YANG BAI Additional Authors: YINGQIAO ZHU, YANYAN FAN Corresponding Author: YINGQIAO ZHU Affiliations: 1st Hospital of Jilin University, 1st Hospital of Jilin University Objective: To investigate the value of contrast-enhanced ultrasound for mesenteric artery stenosis Methods: 68 cases suspected of superior mesenteric artery stenosis by color Doppler sonography underwent CEUS examination, all the patients underwent CT angiography (CTA) examination or digital subtraction angiography (DSA), as a reference Apoptosis inhibitor standards. Under supine resting state, learn more on the right elbow shallow intravenous bolus injection of ultrasound contrast agent (SonoVue) 1.5 ml, Siemens s2000, 4s-1 probe, scan mode at angiography, recording the whole process of enhanced and playback analysis arterial contrast agent arrival time, the superior mesenteric contrast agent filling process. Diameter stenosis is defined as: mild stenosis <50%; moderate stenosis of 50% to 75%; severe stenosis >75%. Moderate and severe stenosis is defined

as a clinically significant stenosis of the superior mesenteric artery. Results: CTA or DSA diagnose 52 cases of clinically significant stenosis. CEUS diagnose clinically significant stenosis 51 cases (17 cases with severe stenosis, moderate stenosis 34 cases), color Doppler ultrasound diagnosis of mesenteric artery stenosis diagnostic specificity and accuracy were 100%, 98.1%, respectively. CEUS diagnostic specificity and accuracy of arterial stenosis of the superior mesenteric artery were 75.0% and 75,0%, respectively. Conclusion: CEUS is a non-invasive, accurate method to diagnose superior mesenteric artery stenosis, which provides important reference information for clinical treatment. Key Word(s): 1. CEUS; 2. superior mesenteric artery; 3.

Accordingly, we designed this study to investigate the clinical association between NAFLD and the development of hypertension. To assess the natural course of blood pressure according to degree of NAFLD (normal, mild, and moderate to severe), we conducted a prospective cohort study on the 22 090 Korean men without hypertension for 5 years. We serially checked the various metabolic factors including systolic and diastolic blood pressure in

order to monitor the development of hypertension. The incidence rate of hypertension increased according to the degree of NAFLD (normal: 14.4%, mild: 21.8%, moderate to severe: 30.1%, P < 0.001). Even after adjusting for other multiple covariates, the hazard ratios (95% confidence intervals) for hypertension were higher in the mild group (1.07; 1.00–1.15) and moderate to severe group (1.14; 1.00–1.30), compared with normal group, respectively check details (P for trend < 0.001). GSI-IX in vivo Development of hypertension is more potentially associated

with the more progressive NAFLD than normal or milder state. In addition, NAFLD was an independent risk factor for hypertension. “
“Previous studies have shown familial aggregation of insulin resistance and nonalcoholic fatty liver disease (NAFLD). Therefore, we aimed to examine whether family history of diabetes mellitus (DM) is associated with nonalcoholic steatohepatitis (NASH) and fibrosis in patients with NAFLD. This was a cross-sectional analysis in participants of the NAFLD Database study and PIVENS trial who had available data on family history of DM. One thousand and sixty-nine patients (63% women), with mean age of 49.6 (± 11.8) years and body mass index (BMI) of 34.2 (± 6.4) kg/m2, were included. Thirty percent had DM, and 56% had a family history of

DM. Both personal history of DM and family history of DM were significantly associated with NASH, with an odds ratio (OR) of 1.93 (95% confidence interval [CI]: 1.37-2.73; P <0.001) and 1.48 (95% CI: 1.11-1.97; P = 0.01) and any fibrosis with an OR of 3.31 (95% CI: 2.26-4.85; P < 0.001) and 1.66 (95% CI: 1.25-2.20; P < 0.001), respectively. When the models were adjusted for age, sex, BMI, ethnicity, and metabolic traits, the association between learn more diabetes and family history of DM with NASH showed an increased adjusted OR of 1.76 (95% CI: 1.13-2.72; P < 0.001) and 1.34 (95% CI: 0.99-1.81; P = 0.06), respectively, and with any fibrosis with a significant adjusted OR of 2.57 (95% CI: 1.61-4.11; P < 0.0001) and 1.38 (95% CI: 1.02-1.87; P = 0.04), respectively. After excluding patients with personal history of diabetes, family history of DM was significantly associated with the presence of NASH and any fibrosis with an adjusted OR of 1.51 (95% CI: 1.01-2.25; P = 0.04) and 1.49 (95% CI: 1.01-2.20; P = 0.04), respectively. Conclusions: Diabetes is strongly associated with risk of NASH, fibrosis, and advanced fibrosis.

1%) cases. A benign disease was found in the other 14 cases, including 35.1% focal chronic pancreatitis 32.4% pseudocysts, 18.5%

pancreatic endocrine tumors (PETs). 1 case of pancreatic solid pseudopapillary tumor and 1 case of pancreatic tuberculosis. Aspiration samples were satisfactory in 51 (96.2%) patients after an average of 2.2 (1–4) passes of the needle. The diagnostic sensitivity of conventional smear cytology, liquid-based cytology and cell block method were 81.5%, 85.4% and 86.9%, respectively. The diagnostic specificity of three methods were all 100%. The diagnostic accuracy were 81.8%, 85.9% and 95.3%, respectively. The Cisplatin diagnostic accuracy rate of the cell block was higher than the conventional smear cytology (P < 0.05) and the liquid-based cytology (P < 0.05). Conclusion: The endoscopic ultrasound-guided fine-needle aspiration biopsy of the cell block might improve the diagnosis accuracy of pancreatic lesions, and the immunohistochemical staining of cell block might help to increase the diagnosis of pancreatic

tumor typing. The cell block has its clinical value in the diagnosis of pancreatic lesions. Key Word(s): 1. EUS; 2. FNA; 3. LPC; 4. cell block; Presenting Author: SOMCHAI AMORNYOTIN Additional Authors: SIRIPORN KONGPHLAY Corresponding Author: SOMCHAI AMORNYOTIN Affiliations: Department of Anesthesiology selleck chemical and Siriraj GI Endoscopy Center, Faculty of Medicine Siriraj Hospital Objective: Unsedated esophagogastroduodenoscopy (UEGD) is safely performed in elderly patients. However, it can induce hemodynamic changes and complications. The aim of this study was to compare and evaluate the complication rate and alteration of blood pressure and heart rate after UEGD procedure between elderly

patients and younger patients. Methods: 1, 918 patients underwent UEGD procedures in two years. All patients who had ASA physical status I-II and no history of hypertension, diabetes and cardiovascular selleck chemicals llc diseases were categorized into the two groups. Patients aged <65 years were in group A, and patients aged ≥65 years were in group B. The primary outcome variable was the complication rate after the procedure. The secondary outcome variables were the alteration of blood pressure and heart rate. Results: After matching gender, weight, ASA physical status and indications of procedure, there were 342 patients in group A and 195 patients in group B. All endoscopies were completely successfully. There were no significant differences in gender, weight, ASA physical status, indication of procedure, hemodynamic parameters, and complications between the two groups. All complications were mild degree, transient and did not require medications. Conclusion: UEGD for elderly patients was safe and effective. Complication rate and alteration of blood pressure and heart rate after UEGD in elderly patients did not higher than in younger patients. Key Word(s): 1. EGD; 2. Unsedated; 3. Hemodynamic; 4.

A cross-sectional study

using 2,643 health check-up subjects (961 patients with GBP and 1,682 age- and sex-matched healthy controls) was conducted. The subjects underwent various laboratory tests, abdominal fat computed tomography (CT), and hepatic ultrasonography. The mean age of the subjects was 51.4 ± 8.3 years, and 74.1% were male. GBPs were significantly associated with fatty liver. Multivariate regression analysis revealed that GBPs were significantly associated with the presence of fatty liver (OR 1.23, 95% CI 1.02-1.48), and adjusting for the HOMA index had little effect on this association (OR 1.23, 95% CI 1.02-1.48). Additionally, GBPs remained significantly associated with the presence of fatty liver after adjustments for CT-measured VAT and SAT (OR 1.24, Dabrafenib in vivo 95% CI 1.03-1.50). The degree of fatty liver showed an independent (OR 1.37 95% CI 1.03-1.80) Erlotinib price and dose-dependent relationship (moderate-severe fatty liver: OR 1.55 95% CI 1.07-2.23, P for trend = 0.014) with large GBPs (≥5mm). Fatty liver, an ectopic regional fat deposit, was found to be closely associated with GBPs independent of known metabolic risk factors, insulin resistance, and CT-measured VAT, confirming a relevant clinical relationship between the two diseases. “
“See article in J. Gastroenterol. Hepatol. 2012; 27: 1371–1376. Direct visualization

of any ductal abnormalities and biopsy can be valuable when the diagnosis of biliary

or pancreatic stricture remains unclear after conventional multi-detector computed tomography (MDCT), magnetic resonance imaging (MRI), endoscopic retrograde cholangio-pancreatography (ERCP) and/or endoscopic ultrasound (EUS) evaluation.1,2 Currently, cholangio-pancreatoscopy, also known as ductoscopy, can be broadly categorized into two-operator and single-operator systems. Despite its availability over the last three decades, the clinical application of the traditional video “mother-baby” cholangioscopy has been limited due to a number of weaknesses. These include instrument fragility, expense, requirement for two-operators, time (approximately an selleck inhibitor extra 30 min to ERCP), only modest image-quality and, most importantly, a lack of accessory channels for biopsy and endotherapy.1 While the new “electronic” video cholangioscopes provide excellent image quality and improve the “visualized” diagnostic accuracy up to 93%,1 the inability to provide tissue diagnosis or endotherapy remains the major drawback. The interest in ductoscopy has been recently revived by the development of single-operator systems that allow both tissue acquisition and endotherapy. The currently available systems are (i) the assisted-cholangioscopy using an ultra-slim gastroscope,3,4 and (ii) SpyGlass Direct Visualization system.

A cross-sectional study

using 2,643 health check-up subjects (961 patients with GBP and 1,682 age- and sex-matched healthy controls) was conducted. The subjects underwent various laboratory tests, abdominal fat computed tomography (CT), and hepatic ultrasonography. The mean age of the subjects was 51.4 ± 8.3 years, and 74.1% were male. GBPs were significantly associated with fatty liver. Multivariate regression analysis revealed that GBPs were significantly associated with the presence of fatty liver (OR 1.23, 95% CI 1.02-1.48), and adjusting for the HOMA index had little effect on this association (OR 1.23, 95% CI 1.02-1.48). Additionally, GBPs remained significantly associated with the presence of fatty liver after adjustments for CT-measured VAT and SAT (OR 1.24, Doxorubicin mouse 95% CI 1.03-1.50). The degree of fatty liver showed an independent (OR 1.37 95% CI 1.03-1.80) selleck inhibitor and dose-dependent relationship (moderate-severe fatty liver: OR 1.55 95% CI 1.07-2.23, P for trend = 0.014) with large GBPs (≥5mm). Fatty liver, an ectopic regional fat deposit, was found to be closely associated with GBPs independent of known metabolic risk factors, insulin resistance, and CT-measured VAT, confirming a relevant clinical relationship between the two diseases. “
“See article in J. Gastroenterol. Hepatol. 2012; 27: 1371–1376. Direct visualization

of any ductal abnormalities and biopsy can be valuable when the diagnosis of biliary

or pancreatic stricture remains unclear after conventional multi-detector computed tomography (MDCT), magnetic resonance imaging (MRI), endoscopic retrograde cholangio-pancreatography (ERCP) and/or endoscopic ultrasound (EUS) evaluation.1,2 Currently, cholangio-pancreatoscopy, also known as ductoscopy, can be broadly categorized into two-operator and single-operator systems. Despite its availability over the last three decades, the clinical application of the traditional video “mother-baby” cholangioscopy has been limited due to a number of weaknesses. These include instrument fragility, expense, requirement for two-operators, time (approximately an learn more extra 30 min to ERCP), only modest image-quality and, most importantly, a lack of accessory channels for biopsy and endotherapy.1 While the new “electronic” video cholangioscopes provide excellent image quality and improve the “visualized” diagnostic accuracy up to 93%,1 the inability to provide tissue diagnosis or endotherapy remains the major drawback. The interest in ductoscopy has been recently revived by the development of single-operator systems that allow both tissue acquisition and endotherapy. The currently available systems are (i) the assisted-cholangioscopy using an ultra-slim gastroscope,3,4 and (ii) SpyGlass Direct Visualization system.

Conclusion: APC can treat esophageal varices classified as LeD0.3Rf0 effectively and safely. Repeated APC on newborn esophageal varices ABT199 with diameter less than 3mmcan reduce the formation of bigger varices and further the possibility of variceal bleeding. Key Word(s): 1. APC; 2. esophageal varices; Presenting Author: ZHANGWEI WEI Additional Authors: LVXIAO PING Corresponding Author: LVXIAO PING Affiliations: guangxi medical university Objective: To analyze and compare the expression level of serum differentially expressed between the proteins of HBV relative liver fibrosis and the healty contral by the technique

of isobaric tags for relative and absolute quantitation (iTRAQ) combined with mass spacetrometry. Methods: 30 cases of HBV relative liver fibrosis and 30 cases of healthy volunteer were selected, after mathced their gender and age, Every find more 10 cases as a group of liver fibrosis or healty contral’ serum, then the serum samples were removed 14 kinds of high-abundant proteins and screened for serum differentially expressed protein was performed by using iTRAQ

labeling and matrix-assisted laser desorption/ionization time-of-fight mass spectrometry, (MALDI-TOF-MS), which the filter conditions are: peptides > 2, Unused > 1.3, Pval < 0.05, 115:113 > 1.2 和 115:113 < 0.8, the last, to analyze these differentially expressed proteins with biological methods by bioinformatics. Results: After conduct database searches, a total of 274 kinds of proteins or peptides were identified in the serum of both HBV relative liver fibrosis and healthy contral by mass spectrometry, with 20 kinds of differentially expressed proteins check details being screened out by setting the filter conditions. In the 20 proteins, the expression level of 13 proteins were up-regulated, while the expression level of 7 proteins were down-regulated. These differentially expressed proteins are involved in 48 kinds of biological precesses, 8 kinds of cellular components and 12 kinds of molecular pathways. The figure of 5 kinds of protein functional interaction network shows that APOC3, CLU, C4B, CRP, APOE is the crossing point of the functional network. Conclusion: It

a highly efficient and reliable method which is iTRAQ labeling combined with MALDI-TOF-MS for the proteins quanlitiative and quantitaitive. These proteins of APOC3, CLU, C4B, CRP and APOE may play an important role in the development and progression of HBV related liver fibrosis Key Word(s): 1. Liver fibosis; 2. HBV; 3. iTRAQ; 4. Serum marker; Presenting Author: SHENYAN HUA Additional Authors: JIANGHAI XING Corresponding Author: JIANGHAI XING Affiliations: guangxi medical university Objective: To investigate the effect of activated hepatocyte growth factor (HGF) on hepatic stellate cells (HSCs) apoptosis and the regulation of Rho pathway. Methods: HSCs were divided into the following groups:①the blank control group: HSCs were cultured alone; ② the control group: a. HSCs were cultured with exogenous HGF (50 ng/ml), b.